Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431161 | 0.66 | HTR2A (0.35) | P4HB | |
| SCHEMBL2428753 | 0.65 | KDM4E (0.31) | — | |
| SCHEMBL2430742 | 0.62 | S100A4 (0.34) | — | |
| SCHEMBL2433179 | 0.57 | HTR1A (0.35) | P4HB | |
| SCHEMBL1612193 | 0.56 | LMNA (0.41) | — | |
| SCHEMBL2429034 | 0.56 | DRD1 (0.39) | P4HB | |
| SCHEMBL281099 | 0.56 | P4HB (0.47) | P4HB | |
| SCHEMBL2994860 | 0.55 | SCN9A (0.52) | — | |
| SCHEMBL2268770 | 0.54 | CYP3A4 (0.56) | P4HB | |
| SCHEMBL281583 | 0.54 | MAPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | P4HB 2273/4885 |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | P4HB 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.